Oxygen Biotherapeutics News and Events
News & Events
Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Company to support a 500+ patient study assessing benefit of levosimendan in septic shock patients
Wednesday, August 6, 2014 8:00 am EDT
Public Company Information:
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS). more..
University of Glasgow Study Demonstrates the Ability of Oxycyte® to Supply Oxygen to Critical Penumbral Tissue in Acute Ischemic Stroke
MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 21, 2012-- Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) announced today that recent research conducted by its partner, Aurum Biosciences (“Aurum”), Glasgow, Scotland, has shown that Oxycyte®, OBI’s proprietary perfluorocarbon-based intravenous emulsion, improves imaging of the penumbra following acute ischemic stroke in a rat model. The penumbra is the region of the brain where blood supply is inadequate to support normal brain function but sufficient to maintain tissue viability for a limited period of time following stroke. It represents potentially salvageable tissue which, if the oxygen supply can be restored, could lead to improved functional outcomes for stroke patients. more..
Oxygen Biotherapeutics and U.S. Navy Expand Collaboration with Cooperative Research & Development Agreement to Study Oxycyte® for Treatment of Hemorrhagic Shock
MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 2, 2012-- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit of San Antonio (NAMRU-SA) to assess the safety and efficacy of Oxycyte® as well as hemoglobin-based oxygen carriers (HBOC) as potential resuscitation treatments for hemorrhagic shock. This latest CRADA is in addition to separate, ongoing research programs in which the U.S. Navy is exploring the therapeutic potential of Oxycyte in the areas of decompression sickness and traumatic brain injury. more..
Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2012
MORRISVILLE, N.C.--(BUSINESS WIRE)--Jul. 24, 2012-- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, today announced results for the fiscal year (FY) ended April 30, 2012. more..
Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte®
Company on Track to Resume Phase IIb Traumatic Brain Injury Trial Later This Year
MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based intravenous and topical drug candidates, today announced it has achieved the critical milestone of securing an exclusive supply of cGMP-compliant Oxycyte®, the Company's proprietary perfluorocarbon based emulsion, that will take the Company through the current Phase II clinical trial for traumatic brain injury (TBI) and well into Phase III trials.
Key to this recent development was the signing of a contract with the manufacturer of cGMP-compliant FtBu, the proprietary, patent-protected active pharmaceutical ingredient in Oxycyte. Per the agreement, Oxygen Biotherapeutics has the exclusive rights to the supply of FtBu manufactured by this supplier. In addition, the Company is now aligned with a California-based contract manufacturer that will produce Oxycyte based on the Company's new scaled-up process for making the emulsion. Results from recent engineering batches made by this new supplier demonstrate that Oxycyte continues to meet all required specifications for product release. more..
Oxygen Biotherapeutics Announces Plan to Regionalize Its Sales & Marketing Efforts for Its Dermacyte(R) Oxygenating Skin Care Product Line
MORRISVILLE, N.C., March 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the Company has modified its sales and marketing effort to focus on the regional U.S. markets of South Florida and North Carolina. Per the plan, promotional efforts will be highly targeted to support existing internal sales efforts, current client sales efforts, and to build brand awareness and grow market share for the Dermacyte brand. This effort is part of an overall program designed to capitalize on the relationships the company has built over the last year in the top markets that have adopted Dermacyte cosmetics into their practices. more..
Oxygen Biotherapeutics and Aurum Biosciences Enter Joint Research Agreement to Develop an Oxycyte® - Based Diagnostic Tool and Therapeutic for Acute Ischemic Stroke
MORRISVILLE, N.C., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, today jointly announced they have signed a long-term agreement to develop a better tool for defining the extent of injury in acute ischemic stroke and for treating this emergency in the important early hours after the attack. At the center of both efforts is Oxygen Biotherapeutics' proprietary, perfluorocarbon-based Oxycyte emulsion, which is known for delivering large amounts of oxygen to the brain. The key to the diagnostic work lies in Aurum's proprietary GOLD (Glasgow Oxygen Level-Dependent) Magnetic Resonance Imaging (MRI) technology, which has already shown great promise in mapping potentially salvageable tissue in the brain after stroke in the brain. more..
Funds breathe new life into Oxygen Biotherapeutics
By DAVID RANII
Posted on Wednesday, Jan. 25, 2012
After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.
In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...
Oxygen Biotherapeutics to Begin Clinical Study to Determine Efficacy of Dermacyte® in Relieving Histamine Induced Pruritus
MORRISVILLE, N.C., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India. The company received formal approval from the hospital's Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne. more..
Oxygen Biotherapeutics Names Two New Board Members With Pharmaceutical Industry, Product and Business Development Emphasis
MORRISVILLE, N.C., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has named Chris A. Rallis, Executive-in-Residence at Pappas Ventures, and Anthony A. DiTonno, President and Chief Executive Officer of Neurogesx Inc., to serve as members of the company's Board of Directors, effective December 15, 2011. The addition of these two directors increases the Board to five members. more...
Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 Million in Gross Proceeds
MORRISVILLE, N.C., Dec 9, 2011 (GlobeNewswire via COMTEX) --
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that it has entered into definitive agreements with institutional investors for up to $7.5 million in gross proceeds. Under the terms of the agreements, Oxygen will issue registered shares of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), and registered warrants ("Warrants") to purchase shares of the Company's common stock, par value $0.0001 per share. The transaction provides for 50% Warrant coverage on the Preferred Stock, based on the number of shares of common stock initially issuable under the Preferred Stock. more...